Combination Devices - Application Landscape

Frost & Sullivan, June 2011, Pages: 68

Medical Device Application Landscape Influenced by the Adoption of Emerging Drug-Device Combinations

Manufacturers to Collaborate with Large Healthcare Companies to Commercialize Their Devices

Minimally invasive combination drug-device approaches are emerging as viable treatment options that can extend survival, decrease organ toxicity, and improve the quality of life of patients with severe indications. Novel developments in technology and supporting clinical data have made a strong case for the adoption of the combination drug-device approach for pathology research. The rapid advances in image-guidance technologies have also made precise and effective application of combination drug-device approach a clinically feasible option. Drug delivery systems have always comprised a vast segment of biomaterials R&D, and this branch of technology development has got a boost from the demand for smart and biocompatible drug delivery devices. Despite its nascence, drug-device combination is demonstrating its efficiency in targeted drug delivery through the adoption of popular approaches involving nanotechnology, photodynamic therapy, and antimicrobial implants, apart from tablets and pills. Combination devices, with their unique construction and drug release profiles, have changed the way drugs are administered. A targeted approach enables the delivery of higher therapeutic dosages while minimizing adverse side effects. It offers greater control over toxicity and bioavailability of dose in addition to continuous therapeutic drug release over prolonged periods.

Through combination techniques, silica nanorattles as drug carriers of anti-tumor drug docetaxel can now be used for sustained and pH-sensitive drug release. Similarly, conventional polymers can be incorporated with nanoparticles to form nano composites for achieving targeted drug delivery. Among the diverse existing platforms, nano-biomaterials under investigation for cancer treatment have garnered significant attention due to their unique features. “Drug delivery devices are inherently complex systems that require the integration of the drug substance, formulation, container closure, and the device for optimum product functionality,” says the analyst of this research. “Nowadays, patient-driven delivery devices incorporating a biologics portfolio are emerging as better alternatives to single-entity devices for providing enhanced therapeutic advantages.” The detection of cancer indications is one of the most important areas of pathology influenced by the integration of combination device. Cancer treatment needs to address the two formidable challenges of tumor heterogeneity and adaptive resistance. As a platform technology, the combination of multiple parameters has the remarkable ability to target tumor markers and deliver agents simultaneously for synergy in addressing the dual challenges of cancer heterogeneity and adaptive resistance.

Customer preference for miniaturized platforms is compelling combination device manufacturers to create implantable devices for diagnostic and therapeutic delivery at the micro to nano levels. As more companies begin to adopt the open innovation model for developing products, inventions will pick up pace steadily across combining drugs, devices, and biologics. To ensure the speed does not slacken, manufacturers have to guard against suboptimal drug products, as the wrong drug mixture can lead to harmful side effects. A poor choice of biomaterials can cause the coating to flake off or too much drug being deposited in the body. Technology developers are still unable to achieve the desired efficacy levels for the therapy sought. Further, they often lack the funds to take the product to the commercialization phase. Therefore, companies often license their products to a large device manufacturer or collaborate with a pharmaceutical company to get the product to the market. “As combination devices is a relatively new concept within the medical devices sector, technology licensing, spin-off companies, and research groups are normally the prevailing model for commercialization, both for emerging companies as well as major participants,” notes the analyst.

Application Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

- Diagnostic tools

- Bacteriophages

- Antibiotics

This Frost & Sullivan research service titled Combination Devices-Application Landscape discusses different combination device platforms in key application segments. This research covers a snapshot of the global corporate and academic initiatives, a dynamic strength, weakness, opportunity, threat (SWOT) analysis of key growth strategies, a technology-specific application analysis, technology roadmap analysis, and scenario modeling with emerging opportunities listing.

1. Executive Summary
- 1.1 Research Scope
- 1.2 Technical Insights--Research Process and Methodology
- 1.3 Key Findings

2. Technology Snapshot and Trends
- 2.1 Overview
- 2.2 Brief on prospective technologies
- 2.3 Technology Capability
- 2.4 Technology Value Chain
- 2.5 Dynamic SWOT Analysis

3. Impact Assessment and Analysis
- 3.1 Market Impact of Key Accelerators
- 3.2 Market Impact of Key Challenges
- 3.3 Impact mapping of Accelerators and Challenges

4. Diffusion of Innovations and Needs Assessment
- 4.1 Technology Development and Adoption Footprint
- 4.2 Product Life Cycle Analysis
- 4.3 Demand Side Analysis--Stakeholder Needs and Analysis

5. Opportunity Evaluation and Roadmapping
- 5.1 Scenario Modelling and Emerging Opportunities
- 5.2 Technology Comparison Analysis
- 5.3 Technology Roadmap

6. Patents
- 6.1 Patent Analysis

7. Key Contacts
- 7.1 Listing of Industry Participants

8. Decision Support Database
- 8.1 Healthcare Expenditure
- 8.2 Cancer Cases
- 8.3 Prevalence of Cardiovascular Diseases
- 8.4 Pharmaceutical R&D Expenditure

9. About Frost & Sullivan

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Transdermal Drug Delivery - Technologies, Markets, and Companies
• Injectable Drug Delivery to 2018 Drugs, Devices, Targets, Therapeutics and Forecasts
• Inhaled Drug Delivery: Devices, Indications, Therapeutics, Markets and Forecasts
• Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
• Implantable Drug Delivery Devices (Contraceptives, Drug Infusion Pumps, Intraocular Implants, Drug Eluting, Bio-Absorbable Stents, Biodegradable) Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
• Nanoparticle Drug Delivery Market Report
• Therapeutic Proteins to 2016. Drugs, Devices, Diseases, Markets and Forecasts
• Personalized Medicine - Scientific and Commercial Aspects
• Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017
• Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017